Naloxone is an effective antidote, but its short half-life means repeated doses, and infusions are often required. We investigated the effectiveness of adding intramuscular naloxone to titrated intravenous naloxone in opioid overdose in preventing recurrence of respiratory depression. This double-blinded randomised placebo-controlled trial was conducted in patients with suspected opioid poisoning and respiratory depression (respiratory rate <10 breaths/min or oxygen saturation <93%). Patients were randomised to receive either intramuscular naloxone 1,600 µg or saline placebo. All patients received titrated intravenous naloxone 100 µg and were managed on an opioid poisoning care pathway. The primary outcome was recurrence of respiratory depression within 4 h. Secondary outcomes were the proportion receiving naloxone infusions, number of naloxone boluses administered, reversal of respiratory depression at 10 min, and precipitation of opioid withdrawal (any symptom). Recurrence of respiratory depression within 4 h was less common in 28/69 (41%) patients receiving intramuscular naloxone versus 48/67 (72%) patients receiving placebo (difference 31%, 95% CI: 13-46%; P < 0.001). Fewer naloxone infusions (5/69; 7% versus 25/67; 37%, difference 30%, 95% CI: 15 to 55%; P < 0.001) and fewer naloxone doses were administered (median 2, IQR: 1 to 5, versus median 5, IQR: 2 to 8; P = 0.001) in the intramuscular group. Reversal of respiratory depression at 10 min was similar between groups (51/69; 74% intramuscular naloxone versus 47/67; 70% placebo; P = 0.703). Opioid withdrawal occurred in 35/69 (51%) given intramuscular naloxone compared to 28/67 (42%) in the placebo group (difference 9%; 95% CI: -8 to 27%; P = 0.308). The favourable pharmacokinetics of intramuscular naloxone, particularly its longer duration of activity, likely explains the improved effectiveness with lower recurrence of respiratory depression. The addition of intramuscular naloxone 1,600 µg to titrated intravenous naloxone prolonged effective reversal of respiratory depression, with fewer naloxone doses and infusions given, and no significant difference in patients developing withdrawal.
Background Few studies of pharmacists’ impact on emergency department resuscitation care have been powered for key outcomes such as medication error and time to administration. Aim To conduct a pilot study to inform the design of a large interventional cohort study to determine if the presence of a pharmacist in an ED resuscitation setting reduces medication errors. Methods A pilot prospective controlled interventional cohort study of patients treated in the emergency department resuscitation area. The incidence of medication errors that occurred when a pharmacist was present (intervention) or absent (control) was collected. The pharmacist’s clinical activities were recorded and a review of study design and methods conducted to determine the feasibility of the study design. A sample size calculation was performed to power a larger study. Results A total of 62 patients were included, of which the pharmacist was present during resuscitation events for 38 (61%). The pharmacist provided clinical activities such as medication advice and double check, pre-emptive medication supply, medication error detection and timely interception, medication history and review. There were one prospectively and six retrospectively identified medication errors (25%) in the control arm and none in the intervention arm. Six errors were intercepted by the pharmacist. The sample size for the larger study was calculated at 40 patients in each arm. Conclusions A pharmacist’s presence during resuscitation events provides expert medication advice and facilitates the safe administration of medications. A larger study of 80 patients is necessary to confirm a significant reduction in medication errors.